Exhibit and Poster Hall Hours
Monday, February 23 · 3:15 pm - 6:45 pm
Tuesday, February 24 · 10:15 am - 3:45 pm
Wednesday, February 25 · Closed

IBC's Inaugural AsiaTIDES is the only event that brings worldwide best practices in development strategies for oligonucleotide and peptide-based therapeutics including formulation and delivery, and regulatory updates—to Japan.

Japanese pharmaceutical companies and academic researchers have become very interested in the promising new field of oligonucleotide- and peptide-based therapeutics. Particularly, interest is growing in the hot fields of siRNA, mRNA, aptamers and related molecules. This event brings advanced developments from around the world to Japan. Highlights are tutorials on analytical and bioanalytical technologies, and on synthesis and purification of RNA/DNA for research through commercial scale. The main conference highlights advances in delivery and formulation, a major challenge in this field; round-up of case studies of compounds in preclinical and clinical development worldwide including optimization and CMC development, and sessions on worldwide regulatory expectations, market landscapes and partnering.

"The concentration of key industry players at TIDES is fantastic; the event is tremendously useful...Almost all the important decision-makers attended TIDES 2008." --Simon May, Ph.D., Global Director, Business-to-Business Sales, Life Science Research, Thermo Fisher Scientific, United Kingdom

Keynote Presentations
	Yoshikazu Nakamura, Ph.D. University of Tokyo; Ribomic Japan		Akira Yamada, Ph.D. Kurume University Research Center for Innovative Cancer Therapy Japan
	Junichi Yano, Ph.D. Nippon Shinyaku Co., Ltd. Japan		Takumi Kawabe, M.D., Ph.D. CanBas Japan
Featured Presentations
	Larry Gold, Ph.D. SomaLogic, Inc. USA		Rachel Meyers, Ph.D. Alnylam Pharmaceuticals USA

"AsiaTIDES: A first-of-its-kind meeting in Asia providing valuable insight into this niche area."
- Philip R. Oldfield, Ph.D., Scientific Director, Immunochemistry, Laboratory Sciences, Charles River Laboratories PCS-MTL, Canada

"The concentration of key industry players at TIDES is fantastic; the event is tremendously useful… Almost all the important decision-makers attended TIDES 2008."
- Simon May, Ph.D., Global Director, Business-to-Business Sales, Life Science Research, Thermo Fisher Scientific, United Kingdom

Attendees Praise the U.S. TIDES Conference

"The conference brought nearly all the experts in oligonucleotide therapeutics area under one roof, which made for an educational and entertaining meeting."
- Sumit Lutara, Senior Scientist, Pfizer, Inc, USA

"TIDES conferences in Europe and USA are always great places to learn about all the different aspects of oligonucleotide manufacturing, new diagnostic and therapeutic applications and ideal venues to network with colleagues and customers. I am excited that this great event now also starts in Asia."
- Peter Haima, Ph.D., Manager IVD Services, Eurogentec S.A., Belgium

"I have participated in TIDES since its inception and find it to be by far the most useful meeting in the field, for both the latest updates on drug development and regulatory issues, and also for networking with industry leaders."
- Michael S. Verlander, D. Phil., Executive Vice President, PolyPeptide Laboratories, Inc., USA and India

About the Organizers
This event is brought to you by the organizers of TIDES Peptide and Oligonucleotide® Technology and Product Development and EuroTIDES conferences, as well as Drug Discovery and Development of Innovative Therapeutics World Congress in Boston and Japan, IBC Life Sciences, an informa business. Other informa businesses include: Datamonitor, MedTRACK, SCRIP and Pharmaprojects. www.IBCLifeSciences.com and www.informa.com

Conference Language
The conference will be conducted in English without translation.